Skip to main content

Wave Life Sciences, Inc.

WVE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001631574

In the last 90 days, Wave Life Sciences, Inc. insiders filed 0 open-market purchases and 4 sales; 239 institutions reported holding it in 13F filings for Q2 2026, worth $1.06B in total; superinvestors Maverick Capital and Duquesne Family Office hold it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Wave Life Sciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
4 filings
4 insiders, $135.1K in total
Insiders trading
4
Net value
−$135.1K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Wave Life Sciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Wave Life Sciences, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Wagner Heidi LDirector44,930Aug 13, 20262
Rawcliffe AdrianDirector0Aug 13, 20263
Takanashi KenDirector20,079Aug 13, 20262
Tan Aik NaDirector24,968Aug 13, 20262
RA Capital Healthcare Fund LPDirector, 10% Owner26,975,505IndirectMar 30, 20262
Ra Capital Management, L.P.Director, 10% Owner26,975,505IndirectMar 30, 20262
Kolchinsky PeterDirector, 10% Owner26,975,505IndirectMar 30, 20262
Shah Rajeev M.Director, 10% Owner26,975,505IndirectMar 30, 20262
Francis ChrisSee Remarks61,867Feb 27, 20264
Vargeese ChandraSee Remarks408,246Feb 11, 20261
Bolno PaulPresident and CEO275,520Feb 11, 20261
Moran KyleChief Financial Officer134,385Feb 11, 20262
GlaxoSmithKline PLC10% Owner18,245,691IndirectDec 15, 20251
Corrigan MarkDirector28,815Dec 10, 20251
Henry Christian ODirector12,700Dec 10, 20251
Verdine Gregory L.Director275,217Dec 10, 20251
Panzara Michael A.See Remarks109,103Jul 27, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 13, 2026 (view filing)9:00 PM ETAug 112 daysWagner Heidi LDirectorSSale−7.00K$6.01−$42.1K−13.5%44.9K after10b5-1
Aug 13, 2026 (view filing)9:00 PM ETAug 121 dayRawcliffe AdrianDirectorSSale−12.7K$5.29−$67.2K−100.0%0 after10b5-1
Aug 13, 2026 (view filing)9:00 PM ETAug 112 daysTakanashi KenDirectorSSale−3.86K$6.01−$23.2K−16.1%20.1K after10b5-1
Aug 13, 2026 (view filing)9:00 PM ETAug 112 daysTan Aik NaDirectorSSale−432$6.01−$2.60K−1.7%25.0K after10b5-1
Mar 30, 2026 (view filing)8:30 PM ETMar 26-304 daysRA Capital Healthcare Fund LP and 3 othersDirector, 10% OwnerPPurchase+8.77M$6.23+$54.6M+48.2%27.0M after4 lots
Feb 27, 2026 (view filing)Feb 261 dayFrancis ChrisSee RemarksSSale−33.2K$15.05−$499.5K−34.9%61.9K after2 lots10b5-1
Feb 11, 2026 (view filing)Feb 92 daysMoran KyleChief Financial OfficerSSale−3.59K$13.45−$48.3K−2.6%134.4K after
Feb 11, 2026 (view filing)Feb 92 daysBolno PaulPresident and CEOSSale−10.5K$13.45−$141.0K−3.7%275.5K after
Feb 11, 2026 (view filing)Feb 92 daysFrancis ChrisSee RemarksSSale−1.88K$13.45−$25.3K−3.0%61.9K after
Feb 11, 2026 (view filing)Feb 92 daysVargeese ChandraSee RemarksSSale−3.23K$13.45−$43.4K−0.8%408.2K after
Jan 6, 2026 (view filing)Jan 24 daysFrancis ChrisSee RemarksSSale−9.38K$16.03−$150.3K−27.3%25.0K after2 lots10b5-1
Dec 15, 2025 (view filing)Dec 114 daysGlaxoSmithKline PLC10% OwnerPPurchase+1.47M$19.00+$27.9M+8.8%18.2M after
Dec 10, 2025 (view filing)Dec 82 daysRawcliffe AdrianDirectorSSale−42.0K$15.00−$630.0K−76.8%12.7K after10b5-1
Dec 10, 2025 (view filing)Dec 82 daysWagner Heidi LDirectorSSale−14.0K$13.50−$189.0K−23.8%44.9K after2 lots10b5-1
Dec 10, 2025 (view filing)Dec 82 daysHenry Christian ODirectorSSale−93.4K$14.65−$1.37M−88.0%12.7K after4 lots10b5-1
Dec 10, 2025 (view filing)Dec 82 daysTan Aik NaDirectorSSale−134.2K$13.58−$1.82M−84.1%25.4K after8 lots10b5-1
Dec 10, 2025 (view filing)Dec 82 daysVerdine Gregory L.DirectorSSale−20.0K$13.47−$269.5K−6.8%275.2K after2 lots10b5-1
Dec 10, 2025 (view filing)Dec 82 daysFrancis ChrisSee RemarksSSale−441.0K$14.58−$6.43M−94.6%25.0K after9 lots10b5-1
Dec 10, 2025 (view filing)Dec 8-92 daysMoran KyleChief Financial OfficerSSale−260.0K$15.78−$4.10M−74.2%90.4K after6 lots10b5-1
Dec 10, 2025 (view filing)Dec 82 daysCorrigan MarkDirectorSSale−16.1K$13.49−$217.3K−35.9%28.8K after2 lots10b5-1
Nov 14, 2025 (view filing)6:14 PM ETNov 131 dayRA Capital Healthcare Fund LP and 3 othersDirector, 10% OwnerPPurchase+1.00K$6.69+$6.69K0.0%18.2M after
Nov 14, 2025 (view filing)Nov 131 dayRawcliffe AdrianDirectorSSale−16.1K$6.79−$109.4K−55.9%12.7K after10b5-1
Aug 26, 2025 (view filing)Aug 224 daysVerdine Gregory L.DirectorSSale−10.0K$10.00−$100.0K−3.4%285.2K after10b5-1
Aug 26, 2025 (view filing)Aug 224 daysBolno PaulPresident and CEOSSale−217.4K$10.10−$2.20M−64.2%121.0K after10b5-1
Aug 19, 2025 (view filing)Aug 154 daysTan Aik NaDirectorSSale−21.0K$9.25−$194.3K−34.2%40.4K after10b5-1
Aug 13, 2025 (view filing)Aug 13Same dayHenry Christian ODirectorSSale−9.67K$8.81−$85.2K−24.6%29.6K after10b5-1
Aug 7, 2025 (view filing)Aug 52 daysTakanashi KenDirectorSSale−4.87K$8.75−$42.6K−0.1%5.72M after10b5-1
Aug 7, 2025 (view filing)Aug 52 daysTan Aik NaDirectorSSale−1.13K$8.75−$9.86K−7.0%15.0K after10b5-1
Jun 13, 2025 (view filing)Jun 13Same dayVerdine Gregory L.DirectorSSale−30.0K$6.95−$208.5K−9.6%282.5K after10b5-1
Mar 21, 2025 (view filing)Mar 201 dayHenry Christian ODirectorSSale−10.5K$9.77−$102.6K−39.5%16.1K after10b5-1
Mar 7, 2025 (view filing)Mar 7Same dayBolno PaulPresident and CEOSSale−169.0K$9.57−$1.62M−33.3%338.4K after10b5-1
Nov 27, 2024 (view filing)Nov 252 daysBolno PaulPresident and CEOSSale−50.0K$15.00−$750.0K−18.7%217.4K after10b5-1
Nov 15, 2024 (view filing)Nov 15Same dayBolno PaulPresident and CEOSSale−51.2K$14.32−$733.7K−19.1%217.4K after10b5-1
Nov 13, 2024 (view filing)Nov 85 daysFrancis ChrisSee RemarksSSale−36.0K$16.00−$576.0K−100.0%0 after10b5-1
Oct 18, 2024 (view filing)Oct 162 daysFrancis ChrisSee RemarksSSale−208.8K$13.67−$2.86M−100.0%0 after4 lots10b5-1
Oct 18, 2024 (view filing)Oct 162 daysBolno PaulPresident and CEOSSale−90.5K$15.00−$1.36M−25.2%268.6K after10b5-1
Oct 1, 2024 (view filing)Sep 274 daysGlaxoSmithKline PLC10% OwnerPPurchase+2.79M$8.00+$22.3M+20.0%16.8M after
Sep 27, 2024 (view filing)Sep 252 daysMoran KyleChief Financial OfficerSSale−17.1K$9.00−$154.3K−46.4%19.8K after10b5-1
Aug 23, 2024 (view filing)Aug 212 daysBolno PaulPresident and CEOSSale−48.4K$5.78−$279.6K−11.9%359.1K after10b5-1
Apr 5, 2024 (view filing)Apr 32 daysMoran KyleChief Financial OfficerSSale−15.6K$6.17−$96.4K−31.5%33.9K after10b5-1
Jan 30, 2024 (view filing)Dec 7, 202354 daysLateGlaxoSmithKline PLC10% OwnerPPurchase+3.30M$5.00+$16.5M+30.9%14.0M after
Jan 17, 2024 (view filing)7:06 PM ETDec 11, 202337 daysRA Capital Healthcare Fund LP and 3 othersDirector, 10% OwnerPPurchase+1.00M$5.00+$5.00M+5.8%18.2M afterAmended
Aug 23, 2023 (view filing)Aug 23Same dayMoran KyleChief Financial OfficerSSale−37.1K$4.75−$176.0K−44.6%46.1K after10b5-1
Feb 17, 2023 (view filing)Feb 161 dayVargeese ChandraSee RemarksSSale−10.2K$4.03−$41.3K−8.8%106.6K after
Feb 17, 2023 (view filing)Feb 161 dayBolno PaulPresident and CEOSSale−29.4K$4.04−$118.8K−6.7%407.4K after
Feb 17, 2023 (view filing)Feb 161 dayFrancis ChrisSee RemarksSSale−10.3K$4.03−$41.3K−11.4%79.7K after
Feb 17, 2023 (view filing)Feb 161 dayMoran KyleChief Financial OfficerSSale−9.73K$4.04−$39.3K−10.9%79.8K after
Jun 21, 2022 (view filing)4:33 PM ETJun 165 daysRA Capital Healthcare Fund LP and 3 othersDirector, 10% OwnerPPurchase+9.48M$2.15+$20.4M+122.8%17.2M after
Jun 21, 2022 (view filing)4:33 PM ETJun 165 daysRA Capital Healthcare Fund LP and 3 othersDirector, 10% OwnerPPurchase+7.09M$2.15+$15.3M–7.09M afterDerivative
May 6, 2022 (view filing)May 51 dayVargeese ChandraSee RemarksSSale−16.7K$1.72−$28.7K−13.1%111.1K after